Nanotechnology Now – Press Release: Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease

Home > Press > Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver DiseaseAbstract:Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-HSD, the...